RegeneRx Biopharmaceuticals, Inc. (RGRX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2022 | 76.76 Thousand USD | 0.01% |
| 2021 | 76.75 Thousand USD | -0.0% |
| 2020 | 76.75 Thousand USD | 0.08% |
| 2019 | 76.69 Thousand USD | 10.22% |
| 2018 | 69.58 Thousand USD | 29.81% |
| 2017 | 53.6 Thousand USD | -42.4% |
| 2016 | 93.07 Thousand USD | 54.07% |
| 2015 | 60.4 Thousand USD | 16547.62% |
| 2014 | -367.28 USD | -101.25% |
| 2013 | 29.29 Thousand USD | -97.82% |
| 2012 | 1.34 Million USD | -11.16% |
| 2011 | 1.51 Million USD | 77.93% |
| 2010 | 849.53 Thousand USD | 0.0% |
| 2009 | - USD | -100.0% |
| 2008 | 168.41 Thousand USD | -29.92% |
| 2007 | 240.32 Thousand USD | -11.8% |
| 2006 | 272.49 Thousand USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | -100.0% |
| 1998 | 3265.00 USD | -98.48% |
| 1997 | 215.03 Thousand USD | -60.34% |
| 1996 | 542.24 Thousand USD | 413.53% |
| 1995 | 105.59 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 Q1 | 19.19 Thousand USD | 0.0% |
| 2023 Q2 | - USD | -100.0% |
| 2023 Q3 | - USD | 0.0% |
| 2022 FY | 76.76 Thousand USD | 0.01% |
| 2022 Q1 | 19.19 Thousand USD | -66.67% |
| 2022 Q2 | 19.19 Thousand USD | 0.0% |
| 2022 Q3 | 19.19 Thousand USD | -0.01% |
| 2022 Q4 | 19.19 Thousand USD | 0.0% |
| 2021 Q2 | 19.19 Thousand USD | 0.0% |
| 2021 Q3 | 19.18 Thousand USD | -0.03% |
| 2021 FY | 76.75 Thousand USD | -0.0% |
| 2021 Q4 | 57.57 Thousand USD | 200.1% |
| 2021 Q1 | 19.19 Thousand USD | 0.01% |
| 2020 Q4 | 19.18 Thousand USD | 0.0% |
| 2020 FY | 76.75 Thousand USD | 0.08% |
| 2020 Q1 | 19.18 Thousand USD | 0.05% |
| 2020 Q2 | 19.18 Thousand USD | -0.01% |
| 2020 Q3 | 19.18 Thousand USD | 0.01% |
| 2019 Q3 | 19.17 Thousand USD | 0.08% |
| 2019 Q2 | 19.16 Thousand USD | -0.06% |
| 2019 Q1 | 19.17 Thousand USD | 0.01% |
| 2019 FY | 76.69 Thousand USD | 10.22% |
| 2019 Q4 | 19.17 Thousand USD | 0.01% |
| 2018 Q2 | 12.48 Thousand USD | -33.46% |
| 2018 Q3 | 19.16 Thousand USD | 53.49% |
| 2018 Q4 | 19.17 Thousand USD | 0.06% |
| 2018 FY | 69.58 Thousand USD | 29.81% |
| 2018 Q1 | 18.76 Thousand USD | 8.24% |
| 2017 Q4 | 17.33 Thousand USD | 25.35% |
| 2017 Q3 | 13.82 Thousand USD | 9.13% |
| 2017 FY | 53.6 Thousand USD | -42.4% |
| 2017 Q1 | 12.67 Thousand USD | -0.09% |
| 2017 Q2 | 12.67 Thousand USD | 0.01% |
| 2016 Q3 | 12.65 Thousand USD | 0.08% |
| 2016 Q4 | 12.68 Thousand USD | 0.21% |
| 2016 Q1 | 55.08 Thousand USD | 447.53% |
| 2016 FY | 93.07 Thousand USD | 54.07% |
| 2016 Q2 | 12.64 Thousand USD | -77.05% |
| 2015 FY | 60.4 Thousand USD | 16547.62% |
| 2015 Q4 | 10.06 Thousand USD | 84.22% |
| 2015 Q1 | 39.96 Thousand USD | 77317.22% |
| 2015 Q3 | 5461.29 USD | 10.97% |
| 2015 Q2 | 4921.54 USD | -87.68% |
| 2014 Q1 | -74.70 USD | 99.75% |
| 2014 Q2 | -149.07 USD | -99.55% |
| 2014 Q4 | -51.75 USD | 44.36% |
| 2014 FY | -367.28 USD | -101.25% |
| 2014 Q3 | -93.02 USD | 37.6% |
| 2013 Q3 | -10.81 USD | 82.65% |
| 2013 Q2 | -62.29 USD | -100.21% |
| 2013 Q1 | 29.48 Thousand USD | -89.51% |
| 2013 FY | 29.29 Thousand USD | -97.82% |
| 2013 Q4 | -29.5 Thousand USD | -272930.9% |
| 2012 Q2 | 541.69 Thousand USD | 140.93% |
| 2012 Q3 | 295.36 Thousand USD | -45.48% |
| 2012 Q4 | 280.95 Thousand USD | -4.88% |
| 2012 FY | 1.34 Million USD | -11.16% |
| 2012 Q1 | 224.83 Thousand USD | -22.3% |
| 2011 Q2 | 588.57 Thousand USD | -2.3% |
| 2011 FY | 1.51 Million USD | 77.93% |
| 2011 Q4 | 289.38 Thousand USD | 828.69% |
| 2011 Q3 | 31.16 Thousand USD | -94.71% |
| 2011 Q1 | 602.45 Thousand USD | -24.29% |
| 2010 Q1 | -22.92 Thousand USD | 0.0% |
| 2010 Q2 | 11.12 Thousand USD | 148.54% |
| 2010 Q3 | 42.69 Thousand USD | 283.59% |
| 2010 FY | 849.53 Thousand USD | 0.0% |
| 2010 Q4 | 795.72 Thousand USD | 1763.95% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 FY | - USD | -100.0% |
| 2009 Q2 | - USD | -100.0% |
| 2009 Q1 | 4.62 Million USD | -76.64% |
| 2008 Q3 | 136.24 Thousand USD | 0.0% |
| 2008 Q4 | 19.78 Million USD | 14418.76% |
| 2008 FY | 168.41 Thousand USD | -29.92% |
| 2008 Q2 | - USD | -100.0% |
| 2008 Q1 | 32.16 Thousand USD | 19.35% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q4 | 26.95 Thousand USD | -87.37% |
| 2007 FY | 240.32 Thousand USD | -11.8% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q3 | 213.37 Thousand USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q2 | -3.59 Million USD | 0.0% |
| 2006 FY | 272.49 Thousand USD | 0.0% |
| 2006 Q3 | -2.07 Million USD | 42.19% |
| 2006 Q4 | - USD | 100.0% |
| 2005 Q4 | - USD | 100.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q1 | -925.02 Thousand USD | -15289.21% |
| 2005 Q2 | -1.01 Million USD | -9.47% |
| 2005 Q3 | -1.45 Million USD | -43.73% |
| 2004 Q4 | 6090.00 USD | 100.62% |
| 2004 Q2 | -364.4 Thousand USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q3 | -983.61 Thousand USD | -169.92% |
| 2003 Q3 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 FY | - USD | -100.0% |
| 1998 FY | 3265.00 USD | -98.48% |
| 1997 FY | 215.03 Thousand USD | -60.34% |
| 1996 FY | 542.24 Thousand USD | 413.53% |
| 1995 FY | 105.59 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 3247.232% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 99.344% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 124.025% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 99.936% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 100.298% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 259.06% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 161.779% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 99.488% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -2374.565% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 99.216% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -16.786% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 324.776% |
| Mesoblast Limited | -35.16 Million USD | 100.218% |
| Marizyme, Inc. | 457.7 Thousand USD | 83.229% |
| Genus plc | 178.7 Million USD | 99.957% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 99.965% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -23.358% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 81.285% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 797.827% |
| ContraFect Corporation | -154 Thousand USD | 149.845% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 253.522% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| IMV Inc. | -962.29 Thousand USD | 107.977% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 119.809% |
| MultiCell Technologies, Inc. | 49.32 USD | -155538.686% |
| ONE Bio Corp. | 20.12 Million USD | 99.619% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 99.809% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -56.975% |
| Q BioMed Inc. | -8988.00 USD | 954.039% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 99.728% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 597.672% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 99.827% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 106.724% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -9.659% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 1650.101% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 45.366% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 178.717% |
| GB Sciences, Inc. | -624.00 USD | 12401.442% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 189.228% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 99.999% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 37004.327% |
| Enzolytics Inc. | 30.7 Thousand USD | -149.971% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 84.089% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 99.993% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 114.919% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 87.567% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.981% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 966.768% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 191.547% |
| Kadimastem Ltd | -630.13 Thousand USD | 112.182% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 92.231% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 99.201% |
| BioStem Technologies, Inc. | 15.42 Million USD | 99.502% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 748.593% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 56.524% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 56.524% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | 94.344% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 364.693% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 82.944% |
| SYBLEU INC | 11.69 Thousand USD | -556.301% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 98.334% |
| Bioxytran, Inc. | -8285.00 USD | 1026.506% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 120.579% |
| Neutra Corp. | 14.33 Thousand USD | -435.48% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 193.611% |
| PureTech Health plc | -1.6 Million USD | 104.789% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 107.667% |
| IXICO plc | 3.27 Million USD | 97.653% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 111.061% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 104.286% |
| CSL Limited | 7.7 Billion USD | 99.999% |
| Cellectis S.A. | 18 Thousand USD | -326.45% |